By Ruma Paul DHAKA (Reuters) - India's Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for em.
COVID-19 vaccine: Bharat Biotech seeks nod to conduct COVAXIN trials in Bangladesh
If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use
Reuters | January 21, 2021 | Updated 13:16 IST
The vaccine, developed with the Indian Council of Medical Research, was given the green light for restricted use in India this month without any efficacy data from a late-stage trial
India s Bharat Biotech has applied to conduct trials in Bangladesh for its coronavirus vaccine recently approved for emergency use at home, a senior official at Bangladesh s main medical research body told Reuters. If allowed to go ahead, this would be the first trial of any coronavirus vaccine in Bangladesh and could give the densely-populated country of more than 160 million faster access to the shot for mass use.
গণস্বাস্থ্যের অ্যান্টিবডি কিটের ট্রায়ালে বিএমআরসির অনুমোদন dainikamadershomoy.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dainikamadershomoy.com Daily Mail and Mail on Sunday newspapers.
Senior Correspondent,
bdnews24.com
Published: 17 Jan 2021 02:37 PM BdST
Updated: 17 Jan 2021 07:09 PM BdST
Bangladeshi drugmaker Globe Biotech has applied for approval to begin clinical trials of its COVID-19 vaccine candidate Bangavax . );
}
Professor Mamun Al Mahtab, who is leading a team of 57 researchers for the trial, submitted the application and relevant papers – around 10,000 pages - to Bangladesh Medical Research Council or BMRC on Sunday. An assistant director there received the application.
The team seeks to conduct the first and second phases of the trial at a unit of a government hospital. The name of the hospital will be disclosed after the approval.
Bangavax Vaccine: Permission sought for clinical trial
Staff Correspondent
Staff Correspondent
The Clinical Research Organization has asked for permission to launch a clinical trial of Covid-19 vaccine Bangavax, developed by Globe Biotech Ltd of Bangladesh.
The organisation, in an application submitted to the Bangladesh Medical Research Council (BMRC) yesterday, sought to hold first and second phase clinical trials, said chief investigator of the trial Prof Mamun Al Mahtab.
Globe Biotech got permission on January 6 from the Directorate General of Drug Administration to manufacture the doses needed in a clinical trial.
If permitted, a team of 57 researchers will decide the dosage in the first phase and examine safety and efficacy in the second.